Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Gila Hornreich"'
Autor:
Andrea Downey, Joan Sorich, Heather Wasserstrom, Milan Potmesil, Howard S. Hochster, Leonard Liebes, Gila Hornreich, Franco M. Muggia, Anne Hamilton
Publikováno v:
Annals of the New York Academy of Sciences. 922:178-187
The i.p. administration of topoisomerase I (Topo I) inhibitors has a pharmacologic advantage over intravenous application, including preservation of the biologically active lactone form. In our ongoing study, patients have received 9-amino-20(S)-camp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d8df6323a1587a16fad4f79e193cd93
https://doi.org/10.1111/j.1749-6632.2000.tb07036.x
https://doi.org/10.1111/j.1749-6632.2000.tb07036.x
Autor:
Gila Hornreich, Shlomi Sagi, Ofer Lavie, Efrat Levy Lahad, Gad Rennert, Rehuven Keidar, Uzi Beller, Yoram Cohen, Ron Auslander, Alon Ben-Arie
Publikováno v:
Gynecologic Oncology. 92:521-524
Objective . Our recent study determined the possible effects and incidence of BRCA1 and BRCA2 germline mutations in uterine serous papillary carcinoma (USPC). The purpose of this study was to determine the incidence of these mutations in an enlarged
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::099a522d46f62a6eeb8bec01cbdf031e
https://doi.org/10.1016/j.ygyno.2003.11.009
https://doi.org/10.1016/j.ygyno.2003.11.009
Autor:
Joan Sorich, Chung Chiang, Milan Potmesil, Maitreyee Hazarika, Leonard Liebes, Howard S. Hochster, Anne Hamilton, Elliot Newman, Franco M. Muggia, Scott Wadler, Gila Hornreich
Publikováno v:
Anti-Cancer Drugs. 13:819-825
We sought to define the tolerance of 9-amino-20(S)-camptothecin (9-AC) when given by the i.p. route to patients with cancer in the peritoneal cavity consisting of nodules that did not exceed 1 cm in maximum diameter. 9-AC was given in six fractions o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e437b0436595b7665424c6dac95da1d4
https://doi.org/10.1097/00001813-200209000-00006
https://doi.org/10.1097/00001813-200209000-00006
Publikováno v:
Obstetrics & Gynecology. 96:28-32
Objective: To determine the possible effects and incidence of BRCA1 and BRCA2 germline mutations in uterine serous papillary carcinoma. Methods: We screened DNA from 12 women with uterine serous papillary carcinoma for BRCA1 and BRCA2 germline mutati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02667dbe21deefc26615dba580c67c74
https://doi.org/10.1097/00006250-200007000-00007
https://doi.org/10.1097/00006250-200007000-00007
Publikováno v:
Gynecologic Oncology. 67:123-126
To better understand the role of germline BRCA mutations in ovarian cancer in Ashkenazi Jews, we tested 29 consecutive patients admitted to our service for the three mutations common in this ethnic group. These mutations are 185delAG and 5382insC in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10cbd14a415fcc8d2138f4d6de6be06c
https://doi.org/10.1006/gyno.1997.4844
https://doi.org/10.1006/gyno.1997.4844
Publikováno v:
Gynecologic oncology. 75(2)
Objectives. Type II endometrial carcinomas are estrogen-independent and have adverse histologic features and a substantially poorer prognosis. No risk factors have been identified. Interestingly, there is a striking clinical and histopathological sim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22bc575c1821e3437f320fa9f6b32b7d
https://pubmed.ncbi.nlm.nih.gov/10525392
https://pubmed.ncbi.nlm.nih.gov/10525392
Publikováno v:
Gynecologic Oncology. 80:422-423
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4639ce49c8d223ed50285317fa68b6a1
https://doi.org/10.1006/gyno.2000.6076
https://doi.org/10.1006/gyno.2000.6076